For example, proinflammatory cytokines such as IL-1 have been shown to impair neurotransmitter homeostasis (e.g., decreased serotonin levels and enhanced glutamatergic excitotoxicity), induce oxidative stress (OS) and neuronal pyroptosis, and lead to mitochondrial dysfunction and synaptic protein lossultimately fostering a bidirectional relationship between epilepsy and depression (Zhu et al., 2006
GLP-1 Support Patches: Key Benefits
Review: Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes A new review article published in the journal Acta Pharmaceutica Sinica B summarizes advancements in drug delivery systems for three main glucagon-like peptide-1 receptor agonists (GLP-1RAs), which are recommended for selected patients with obesity or type 2 diabetes, depending on indication, comorbidities, and treatment goals
In the STEP 1 to STEP 4 studies, 1% to 2% of semaglutide patients reduced their dose of lipid-lowering medication versus 0 to 1% with placebo, and 1% to 4% of patients in the semaglutide group had a dose increase versus 2% to 5% of placebo patients
Genetic insight into peptide pathways also informs whether oral or injection formulations suit your metabolism better, and whether microdose protocols might accelerate results with fewer side effects
This ratio exceeds what most individuals achieve through diet alone
